Interstitial pneumonia during treatment with rituximab

• Authors: Dominika Leś , Anna Polakiewicz-Gilowska , Beata Kaleta , Danuta Starzyczny-Słota , Elżbieta Nowara
• Languages of publication: EN

Abstracts

EN

Rituximab (RTX) is a chimeric anti-CD20 antibody. It plays an important role in the treatment of B-cell lymphomas and diseases of autoaggression. RTX-induced lung disease is a rare entity, which should be considered in those patients treated with RTX who present with pulmonary disorders with no clear evidence of infection. A 37-year-old woman suffering from CD20-positive DLBCL (diffuse large B-cell lymphoma) received two cycles of the R-CHOP (RTX, cyclophosphamide, doxorubicin, vincristine and prednisone) regimen. After the second cycle of immunochemotherapy, symptoms of interstitial pneumonia occurred. Having excluded all the other causes, it was diagnosed as a complication associated with the administration of RTX.

Keywords

EN

complications; interstitial pneumonia; rituximab

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2015
• Volume: 5
• Issue: 1
• Pages: A16-A20

Contributors

author

Dominika Leś

• Clinical and Experimental Oncology Clinic Oncology Centre, Maria Sklodowska-Curie Institute of Oncology, Gliwice

author

Anna Polakiewicz-Gilowska

• Clinical and Experimental Oncology Clinic Oncology Centre, Maria Sklodowska-Curie Institute of Oncology, Gliwice

author

Beata Kaleta

• Clinical and Experimental Oncology Clinic Oncology Centre, Maria Sklodowska-Curie Institute of Oncology, Gliwice

author

Danuta Starzyczny-Słota

• Clinical and Experimental Oncology Clinic Oncology Centre, Maria Sklodowska-Curie Institute of Oncology, Gliwice

author

Elżbieta Nowara

• Clinical and Experimental Oncology Clinic Oncology Centre, Maria Sklodowska-Curie Institute of Oncology, Gliwice

References

• Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
• Cha SI, Choi KJ, Shin KM et al. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma. Respiration 2013; 85(2): 175.
• Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E. et al. A possible role of 18F-FDG positron – emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkins lymphoma. Haematologica 2008; 93: 1267-69.
• Kanelli S, Ansell SM, Habermann T et al. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leukemia and Lymphoma 2001; 42(6): 1329-37.
• Byrd JC, Peterson BL, Morrison VA et al. Randomized phase 2 study of fludarabine, with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood 2003; 101(1): 6-14.
• Alexandrescu DT, Dutcher JP, O’Boyle K et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leukemia and Lymphoma 2004; 45(11): 2321-25.
• Hainsworth JD, Litchy S, Lamb MR et al. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin’s lymphoma: phase II trial. Clin Lymphoma 2003; 4: 36-42.
• Burton C, Kaczmarski R, Jan-Mohamed R et al. Interstitial pneumonitis related to rituximab therapy. The New England Journal of Medicine 2003; 348(26): 2690-91.
• Julien V, Perrin C, Peyrade F et al. A case of acute respiratory failure related to rituximabtherapy. Rev Mal Respir 2004; 21: 407-10.
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treatment Reviews 2005; 31(6): 456-73.

• Document Type: article